Treatment of Marburg Variant Multiple Sclerosis with Mitoxantrone

Journal of Neuroimaging

Volumn 14, Issue 1, 2004, Pages 58-62

  Jeffery, Douglas R ^a   Lefkowitz, David S ^a   Crittenden, Jeffrey P ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b High County Neurology   (United States)

Author keywords

Marburg MS; Mitoxantrone; MRI

Indexed keywords

CORTICOSTEROID; METHYLPREDNISOLONE; MITOXANTRONE;

ADULT; ARTICLE; BRAIN DISEASE; BRAIN STEM; CASE REPORT; DEMYELINATING DISEASE; DIAGNOSTIC IMAGING; FEMALE; HUMAN; MARBURG VARIANT MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS; NEURORADIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; TREATMENT OUTCOME; WHITE MATTER;

ADULT; ANTI-INFLAMMATORY AGENTS; BRAIN; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MITOXANTRONE; MULTIPLE SCLEROSIS;

EID: 0346749394     PISSN: 10512284     EISSN: None     Source Type: Journal    
DOI: 10.1177/1051228403259393     Document Type: Article

References (13)

1. Marburg O. Die sogennnte "akute Multiple Sklerosis" (Encephalomyelitis periacialis scleroticans). J Psychiat Neurol 1906;27:211-312.
2. Johnson MD, Lavin P, Whetsell WO Jr. Fulminant monophasic multiple sclerosis, Marburg's type. J Neurol 1990;53: 918-921.
3. Mendez MF, Pogacar S. Malignant monophasic multiple sclerosis or "Marburg's disease." Neurology 1988;38:1153-1155.
4. Rodriguez M, Karnes WE, Bartleson JD, Pineda AA. Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination. Neurology 1993;43:1100-1104.
5. Weinshenker B, O'Brien P, Petterson T, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999;46: 878-886.
6. Fidler JM, DeJoy SQ, Gibbons JJ Jr. Selective immunomodulation by the antineoplastic agent mitoxantrone: I. suppression of B lymphocyte function. J Immunol 1986;137: 727-732.
7. Fidler JM, DeJoy SQ, Smith FR III, Gibbons JJ Jr. Selective immunomodulation by the antineoplastic agent mitoxantrone: II. nonspecific adherent suppressor cells derived from mitoxantrone-treated mice. J Immunol 1986;136:2747-2754.
8. Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo controlled, double-blind, randomized, multicentre trial. Lancet 2002;360:2018-2025.
9. Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol 1997;62:112-118.
10. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for MS. Ann Neurol 2001;50:121-127.
11. Kepes JJ. Large focal tumor-like demyelinating lesions of the brain: intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis? A study of 31 patients. Ann Neurol 1993;33:18-27.
12. Kappos L, Gold R, Kunstler E, et al. Mitoxantrone (Mx) in the treatment of rapidly progressive MS: a pilot study with serial gadolinium (Gd)-enhanced MRI. Neurology 1990; 4(suppl 1):261.
13. Krapf H, Mauch E, Fetzer U, Laufen H. Treatment of multiple sclerosis with mitoxantrone. Eur Arch Psychiatry Clin Neurosci 1992;242:96-102.